By Michael SusinGSK said it has sold a stake in Haleon valued around 978 million pounds ($1.24 billion), reducing its stake in the consumer-healthcare business to around 4.2%. The British pharmaceutical giant said Wednesday that it has sold 300 million Haleon shares at an offer price of 326 pence a share. This represents a discount of 2.3% from Tuesday's closing price of 333.6 pence prior to the announcement.

Source: Wall Street Journal January 17, 2024 07:51 UTC